Ochsner Health
Ochsner Health System Formulary
Formulary Addition Request
Questions or Suggestions?
Search by name
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Black Box Warning
HazD
Look Alike Sound Alike
Ambulatory
Do Not Crush
REMS
Antibiotic IV Push Administration
Vaccine
SDS Online
Do Not Crush
OHS Pharmacy Contact
Louisiana Poison Control(800) 222-1222
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
Boards
Ochsner Health COVID-19 SharePoint Site
"Safety On Site"
Click here
to enter an S.O.S.
Physician
Nurse
Partners
Medications listed are available on OH EPIC Formulary, unless otherwise noted.
Not all formulary medications are available at each facility. Please refer to your local
pharmacy
for available inventory.
Ochsner Health
Ochsner Health System Formulary
Formulary Addition Request
Questions or Suggestions?
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Black Box Warning
HazD
Look Alike Sound Alike
Ambulatory
Do Not Crush
REMS
Antibiotic IV Push Administration
Vaccine
SDS Online
Do Not Crush
OHS Pharmacy Contact
Louisiana Poison Control(800) 222-1222
Webpage Links
Search results for:
vutrisiran
vutrisiran
Drug Name
Form
Strength
Infusion Center Available
Restricted
Non-formulary
Ambulatory Available
Interchange
REMS
Amvuttra
SOLUTION, SUBCUTANEOUS
25 mg/0.5 mL
VIEW MORE
Other Miscellaneous Therapeutic Agents
CLASS
929200
Additional Information and Links
Formulary restrictions
:
Indication
: polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR)
Service line
: Cardiology, Neurology
Formulary location
: Outpatient Infusion, Ambulatory
Service location
: Heart Failure Clinic/Infusion, Ambulatory/ID Infusion
Patient population
: adults
Prior authorization required
: Yes
Restriction/criteria of use
(all will apply unless specified):
Confirmed diagnosis of hATTR-PN with documentation of a mutation in the TTR gene
Currently experiencing signs and symptoms of polyneuropathy, including peripheral or autonomic
Complete electromyography (EMG) of bilateral lower extremities for evidence of polyneuropathy
No concomitant use of a TTR-lowering agent (e.g., inotersen (Tegsedi) and patisiran (Onpattro))
No prior or planned liver transplantation
No known other forms of neuropathy
Last updated:
Sep. 14, 2023
Ambulatory:
Ambulatory/ID Infusion
UpToDate
Lexicomp
DailyMed Package Inserts
Johns Hopkins Guides
Formulary restrictions: